<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005944</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067833</org_study_id>
    <secondary_id>FRE-FNCLCC-97018</secondary_id>
    <secondary_id>EU-20010</secondary_id>
    <nct_id>NCT00005944</nct_id>
  </id_info>
  <brief_title>Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer</brief_title>
  <official_title>Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor
      cells.

      PURPOSE: Randomized phase II trial to compare the effectiveness of second-look surgery with
      or without intraperitoneal infusions of mitomycin and fluorouracil in treating patients who
      have colorectal cancer that is recurrent to the peritoneum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the effect of second look surgery with or without intraperitoneal
      mitomycin and fluorouracil on the 3 year survival rate of patients with colorectal cancer who
      are at high risk for peritoneal cavity cancer. II. Compare the quality of life of patients
      treated with these regimens. III. Compare the toxicity of these regimens in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      center, risk group, presence of symptoms (yes vs no), and isolated disease (yes vs no). After
      primary surgery, all patients receive 6 months of chemotherapy consisting of leucovorin
      calcium IV followed by fluorouracil IV over 10 minutes on days 1-5 every 4 weeks. Patients
      then undergo second look surgery or laparoscopy at 8-12 months. Second look surgery or
      laparoscopy may be performed earlier if markers increase progressively for unknown reasons or
      symptoms of peritoneal cancer occur. Patients with recurrent disease that can be resected are
      randomized to one of two treatment arms. Patients with no residual disease or with
      unresectable disease are followed for survival. Arm I: Patients undergo complete resection of
      all detectable lesions followed immediately by intraperitoneal (IP) mitomycin on day 0 and
      fluorouracil IP on days 1-4. Patients also receive systemic chemotherapy consisting of
      leucovorin calcium IV over 2 hours and fluorouracil IV bolus, followed by fluorouracil IV
      over 22 hours on days 1 and 2. Systemic chemotherapy repeats every 2 weeks for 6 months. Arm
      II: Patients undergo complete or partial resection and then receive systemic chemotherapy as
      in arm I. Quality of life is assessed at baseline and then every 4 months for 3 years. All
      patients (including nonrandomized patients) are followed every 4 months for 3 years.

      PROJECTED ACCRUAL: A total of 152 patients (76 randomized) will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Primary diagnosis of adenocarcinoma of the colon or rectum and
        meeting one of the following risk criteria during the primary surgery: Perforated bowel
        (spontaneous or not) Occlusion Peritoneal deposits Invasion of serosa of more than 4 cm
        diameter Concurrent ovarian metastases Randomization eligibility: Presence of proven
        recurrent peritoneal disease (only one micronodule of 1 mm sufficient) at second look
        laparotomy Total resection of macroscopic lesions possible (local recurrence, lymph node or
        hepatic metastases)

        PATIENT CHARACTERISTICS: Age: 70 and under Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: WBC at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.4 mg/dL
        Cardiovascular: No cardiac condition that would increase surgical risk Pulmonary: No
        pulmonary condition that would increase surgical risk Other: No other condition that would
        increase surgical risk No other malignancy within the past 5 years except basal cell skin
        cancer

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No
        other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy
        Radiotherapy: No concurrent anticancer radiotherapy Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Elias, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital L'Archet - 2</name>
      <address>
        <city>Nice</city>
        <zip>F-06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.R. de Nimes - Hopital Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR D'Orleans - Hopital de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>March 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2004</study_first_posted>
  <last_update_submitted>April 23, 2011</last_update_submitted>
  <last_update_submitted_qc>April 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>liver metastases</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

